Natixis’s Tectonic Therapeutic TECX Stock Holding History

Natixis’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-73,333	Closed	-$627K	–	1239
2022 Q4	$627K	Buy	+73,333	New	+$645K	﹤0.01%	688

Other funds holding TECX

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis's TECX Position: Q1 2023 in Review

Natixis sold out of Tectonic Therapeutic (TECX) in Q1 2023, closing a stake of 73,333 shares — an estimated $627K sold.

Natixis first reported a position in TECX in Q4 2022 and held it in 1 quarter. The position peaked at $627K in Q4 2022. 48 funds tracked by Wall St. Rank hold TECX as of Q1 2023.

Natixis reported no remaining Tectonic Therapeutic position as of Q1 2023 after selling out during the quarter.
Natixis sold 73,333 Tectonic Therapeutic shares in Q1 2023, an estimated $627K.
Natixis first reported a position in Tectonic Therapeutic in Q4 2022 and held it in 1 quarter.
Natixis's Tectonic Therapeutic position peaked at $627K in Q4 2022.
48 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2023.

Based on Natixis's 13F filing for Q1 2023, filed 12 May 2023.